Pemphigus clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
open to eligible people ages 18 years and up
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active, pemphigus vulgaris
Sacramento, California and other locations
Our lead scientists for Pemphigus research studies include Mehrdad Abedi, MD.
Last updated: